Clene (CLNN) Competitors $4.09 -0.57 (-12.23%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLNN vs. ELDN, CKPT, BDTX, NLTX, IVA, ABOS, ELUT, FTLF, IXHL, and SGMTShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Black Diamond Therapeutics (BDTX), Neoleukin Therapeutics (NLTX), Inventiva (IVA), Acumen Pharmaceuticals (ABOS), Elutia (ELUT), FitLife Brands (FTLF), Incannex Healthcare (IXHL), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Clene vs. Eledon Pharmaceuticals Checkpoint Therapeutics Black Diamond Therapeutics Neoleukin Therapeutics Inventiva Acumen Pharmaceuticals Elutia FitLife Brands Incannex Healthcare Sagimet Biosciences Clene (NASDAQ:CLNN) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Do insiders & institutionals have more ownership in CLNN or ELDN? 23.3% of Clene shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 25.1% of Clene shares are held by insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, CLNN or ELDN? Clene has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Do analysts recommend CLNN or ELDN? Clene currently has a consensus target price of $71.33, indicating a potential upside of 1,644.09%. Eledon Pharmaceuticals has a consensus target price of $16.00, indicating a potential upside of 315.58%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CLNN or ELDN? Clene received 42 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. Likewise, 78.41% of users gave Clene an outperform vote while only 72.97% of users gave Eledon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCleneOutperform Votes6978.41% Underperform Votes1921.59% Eledon PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% Does the media prefer CLNN or ELDN? In the previous week, Clene had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 16 mentions for Clene and 12 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.54 beat Clene's score of 0.27 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CLNN or ELDN more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. Eledon Pharmaceuticals' return on equity of -189.99% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets Clene-8,556.77% -1,106.30% -85.11% Eledon Pharmaceuticals N/A -189.99%-28.17% Which has preferable valuation & earnings, CLNN or ELDN? Clene has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$650K52.60-$49.50M-$5.28-0.77Eledon PharmaceuticalsN/AN/A-$116.54M-$2.01-1.92 SummaryClene beats Eledon Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricClenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.96M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.774.8587.8613.46Price / Sales52.60374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book-8.3510.216.946.30Net Income-$49.50M$153.61M$119.12M$225.93M7 Day Performance-12.79%-2.00%-1.84%-1.32%1 Month Performance-28.37%-7.47%-3.65%0.60%1 Year Performance-55.15%31.80%31.64%26.23% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.1607 of 5 stars$4.09-12.2%$71.33+1,644.1%-56.6%$38.96M$650,000.00-0.77100Analyst RevisionHigh Trading VolumeELDNEledon Pharmaceuticals2.9405 of 5 stars$3.85-0.8%$16.00+315.6%+210.5%$153.86MN/A0.0010Analyst ForecastAnalyst RevisionCKPTCheckpoint Therapeutics3.4927 of 5 stars$3.38flat$12.00+255.0%+62.5%$152.16M$100,000.000.0010Analyst RevisionBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.43-4.7%$15.50+537.9%+8.0%$144.29MN/A0.0090Positive NewsNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeIVAInventiva3.0751 of 5 stars$2.74flat$14.00+410.9%-31.9%$143.79M$18.91M0.00100News CoverageABOSAcumen Pharmaceuticals2.6635 of 5 stars$2.37-0.8%$9.00+279.7%+0.4%$143.59MN/A0.0051Analyst RevisionELUTElutia2.685 of 5 stars$4.38+4.0%$10.00+128.3%+170.4%$143.39M$24.75M0.00180FTLFFitLife Brands4.0645 of 5 stars$31.83+2.3%$40.00+25.7%+59.9%$143.01M$52.70M18.8320Analyst RevisionIXHLIncannex Healthcare1.3552 of 5 stars$2.09-2.8%N/A+132.2%$136.48M$10,000.000.003Gap UpSGMTSagimet Biosciences2.1861 of 5 stars$4.52+2.5%$21.60+377.9%+50.2%$135.28M$2M0.008 Related Companies and Tools Related Companies ELDN Competitors CKPT Competitors BDTX Competitors NLTX Competitors IVA Competitors ABOS Competitors ELUT Competitors FTLF Competitors IXHL Competitors SGMT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLNN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLNN Stock Alerts